-
公开(公告)号：US20180022753A1
公开(公告)日：2018-01-25
申请号：US15718431
申请日：2017-09-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James R. Corte , Tianan Fang , Carl P. Decicco , Donald J.P. Pinto , Karen A. Rossi , Zilun Hu , Yoon Jeon , Mimi L. Quan , Joanne M. Smallheer , Yufeng Wang , Wu Yang
IPC: C07D487/04 , C07D487/14 , C07D471/14 , C07D487/18 , C07D471/18 , C07D498/06 , C07D487/16 , C07D487/06 , C07D498/08 , C07D498/04 , C07D487/08
CPC classification number: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
公开(公告)号：US09738655B2
公开(公告)日：2017-08-22
申请号：US14777763
申请日：2014-03-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Donald J. P. Pinto , Charles G. Clarke , Leon M. Smith, II , Michael J. Orwat , Yoon Jeon , James R. Corte
IPC: A61K31/00 , C07D491/107 , C07D401/14 , C07D405/14 , C07D413/14 , C07D401/06 , C07D413/04 , C07D413/06 , C07D417/14 , C07D471/10 , C07D487/04 , C07D491/10
CPC classification number: C07D491/107 , C07D401/06 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/06 , C07D413/14 , C07D417/14 , C07D471/10 , C07D487/04 , C07D491/10
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
公开(公告)号：US09428504B2
公开(公告)日：2016-08-30
申请号：US14418011
申请日：2013-07-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Carl Thibeault , Charles G. Clark , Indawati DeLucca , Carol Hui Hu , Yoon Jeon , Patrick Y. S. Lam , Jennifer X. Qiao , Wu Yang , Yufeng Wang , Tammy C. Wang
IPC: C07D471/10 , C07D519/00
CPC classification number: C07D471/10 , C07D519/00
Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.
-
公开(公告)号：US11136327B2
公开(公告)日：2021-10-05
申请号：US16691099
申请日：2019-11-21
Applicant: Bristol-Myers Squibb Company
Inventor： James R. Corte , Tianan Fang , Carl P. Decicco , Donald J. P. Pinto , Karen A. Rossi , Zilun Hu , Yoon Jeon , Mimi L. Quan , Joanne M. Smallheer , Yufeng Wang , Wu Yang
IPC: C07D487/04 , C07D487/08 , C07D498/08 , C07D487/06 , C07D487/16 , C07D498/06 , C07D471/18 , C07D487/18 , C07D471/14 , C07D487/14 , C07D498/04
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
公开(公告)号：US09802939B2
公开(公告)日：2017-10-31
申请号：US14578846
申请日：2014-12-22
Applicant: Bristol-Myers Squibb Company
Inventor： James R. Corte , Tianan Fang , Carl P. Decicco , Donald J. P. Pinto , Karen A. Rossi , Zilun Hu , Yoon Jeon , Mimi L. Quan , Joanne M. Smallheer , Yufeng Wang , Wu Yang
IPC: C07D487/18 , C07D487/04 , C07D487/08 , C07D498/08 , C07D487/06 , C07D487/16 , C07D498/06 , C07D471/18 , C07D471/14 , C07D487/14 , C07D498/04
CPC classification number: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
Patent Agency Ranking
公开(公告)号：US09108981B2
公开(公告)日：2015-08-18
申请号：US14528168
申请日：2014-10-30
Applicant: Bristol-Myers Squibb Company
Inventor： Patrick Y. S. Lam , Charles G. Clark , James R. Corte , William R. Ewing , Paul J. Gilligan , Yoon Jeon , Wu Yang , Leon M. Smith, II , Yufeng Wang
IPC: C07D498/06 , C07D471/06 , C07D487/06 , C07D498/08 , C07D471/08 , C07D487/08
CPC classification number: C07D498/08 , C07D471/06 , C07D471/08 , C07D487/06 , C07D487/08 , C07D498/06
Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（Ia）化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
7.发明申请TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS 有权含有替代物的四氢喹啉作为因子XIA抑制剂公开(公告)号：US20160145263A1
公开(公告)日：2016-05-26
申请号：US14777763
申请日：2014-03-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Donald J. P. Pinto , Charles G Clarke , Leon M Smith, II , Michael J Orwat , Yoon Jeon , James R Corte
IPC: C07D491/107 , C07D413/06 , C07D417/14 , C07D413/14 , C07D487/04 , C07D401/06 , C07D401/14
CPC classification number: C07D491/107 , C07D401/06 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/06 , C07D413/14 , C07D417/14 , C07D471/10 , C07D487/04 , C07D491/10
Abstract: The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
8.发明申请公开(公告)号：US20150166538A1
公开(公告)日：2015-06-18
申请号：US14418011
申请日：2013-07-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Carl Thibeault , Charles G. Clark , Indawati DeLucca , Carol Hui Hu , Yoon Jeon , Patrick Y.S. Lam , Jennifer X. Qiao , Wu Yang , Yufeng Wang , Tammy C. Wang
IPC: C07D471/10 , C07D519/00
CPC classification number: C07D471/10 , C07D519/00
Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.
Abstract translation: 本发明提供式（I）化合物：如说明书中所定义和包含任何这些新化合物的组合物。 这些化合物是P2Y1受体的拮抗剂，可用作治疗和/或预防血栓栓塞障碍的药物。
-
公开(公告)号：US20150112058A1
公开(公告)日：2015-04-23
申请号：US14578846
申请日：2014-12-22
Applicant: Bristol-Myers Squibb Company
Inventor： James R. Corte , Tianan Fang , Carl P. Decicco , Donald J.P. Pinto , Karen A. Rossi , Zilun Hu , Yoon Jeon , Mimi L. Quan , Joanne M. Smallheer , Yufeng Wang , Wu Yang
IPC: C07D498/06 , C07D487/16 , C07D487/06
CPC classification number: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或fXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号：US20150057262A1
公开(公告)日：2015-02-26
申请号：US14528168
申请日：2014-10-30
Applicant: Bristol-Myers Squibb Company
Inventor： Patrick Y.S. Lam , Charles G. Clark , James R. Corte , William R. Ewing , Paul J. Gilligan , Yoon Jeon , Wu Yang , Leon M. Smith, II , Yufeng Wang
IPC: C07D498/08 , C07D471/08 , C07D487/08
CPC classification number: C07D498/08 , C07D471/06 , C07D471/08 , C07D487/06 , C07D487/08 , C07D498/06
Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（Ia）化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.047 seconds)
